Tanja Obradovic, Therapeutic Strategy Lead of Oncology at Novotech, Senior Advisor of Oncology Drug Development at HopeAI, shared a post on LinkedIn:
“First line therapy for triple negative breast cancer (TNBC) is changing today with first PD-1 inhibitor plus Trop-2-directed antibody drug conjugate (ADC) regimen in advanced TNBC now available.
FDA just approved KEYTRUDA (pembrolizumab, Merck) as IV or SC form in combination with Trodelvy (sacituzumab govitecan-hziy, Gilead Sciences), a Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10) based on Phase 3 KEYNOTE-D19/ASCENT-04 trial.
Outstanding change for TNBC patients who will have a choice of therapy that does not have chemo backbone. Very telling difference is that patients receiving Trodelvy and Keytruda combination tolerated regimen much better than SOC Keytruda chemo combo with treatment discontinuation due to adverse events for only 12% of patients, compared to 31% in the chemotherapy and Keytruda control arm.
Congratulations to team and outstanding leader of women’s cancer group Gursel Aktan who continue delivering outstanding breakthroughs for patients.”
